Primecap Management Co. CA increased its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 26.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,472,020 shares of the company's stock after purchasing an additional 520,950 shares during the period. Primecap Management Co. CA owned about 4.94% of Immunocore worth $76,954,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of IMCR. SG Americas Securities LLC boosted its holdings in Immunocore by 1,867.3% during the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company's stock valued at $5,435,000 after purchasing an additional 152,207 shares in the last quarter. Candriam S.C.A. boosted its stake in Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock valued at $10,621,000 after buying an additional 124,417 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Immunocore in the second quarter valued at $3,686,000. Janus Henderson Group PLC raised its stake in Immunocore by 45.8% during the first quarter. Janus Henderson Group PLC now owns 257,080 shares of the company's stock worth $16,711,000 after acquiring an additional 80,748 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Immunocore by 16.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company's stock valued at $13,470,000 after acquiring an additional 55,463 shares during the period. 84.50% of the stock is currently owned by institutional investors.
Immunocore Trading Up 0.5 %
Shares of IMCR stock traded up $0.16 during trading hours on Friday, reaching $32.28. The company had a trading volume of 193,931 shares, compared to its average volume of 513,105. Immunocore Holdings plc has a 1-year low of $29.72 and a 1-year high of $76.98. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -33.81 and a beta of 0.72. The company has a 50 day moving average of $32.32 and a 200 day moving average of $37.90.
Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company's quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. On average, equities research analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current year.
Wall Street Analysts Forecast Growth
IMCR has been the subject of a number of recent analyst reports. Oppenheimer reiterated an "outperform" rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. UBS Group initiated coverage on shares of Immunocore in a report on Thursday, October 24th. They set a "sell" rating and a $24.00 price objective for the company. Needham & Company LLC reduced their target price on Immunocore from $78.00 to $71.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Barclays dropped their price target on Immunocore from $92.00 to $66.00 and set an "overweight" rating for the company in a report on Friday, August 9th. Finally, Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $69.18.
Get Our Latest Analysis on IMCR
Immunocore Company Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
